Synapse - Genitourinary Oncology Service

Results (369)

Survivorship care

Book Section

Tonorezos, E.; Baxi, S. S.; Blinder, V.; Feldman, D. R.; Friedman, D. N.; Matasar, M.; Salz, T.; Shahrokni, A.; Oeffinger, K. C.
In The American Cancer Society (Eds.) The American Cancer Society's Principles of Oncology: Prevention to Survivorship (2018)

Fulltext@MSK | Save

Refining actionable HER2 alterations in lung cancers through next generation sequencing (NGS)

Meeting Abstract

Xu, C.; Myers, M.; Buonocore, D. J.; Razavi, P.; Shen, R.; Lai, W. C. V.; Smyth, L. M.; Zheng, T.; Ni, A.; Solit, D. B.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors

Meeting Abstract

Wu, J.; Freites-Martinez, A.; Hellmann, M. D.; Rosenberg, J. E.; Motzer, R. J.; Chapman, P. B.; Rizvi, N. A.; Geskin, L. J.; Reed, V. A.; Dusza, S. W.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts)

Meeting Abstract

Wei, X. X.; Lundgren, K.; Teo, M. Y.; Rosenberg, J. E.; Koshkin, V. S.; Grivas, P.; Carril, L.; Castellano, D. E.; Velho, P.; Hahn, N. M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC)

Meeting Abstract

Voss, M. H.; Novik, J. B.; Hellmann, M. D.; Ball, M.; Hakimi, A. A.; Miao, D.; Margolis, C.; Horak, C.; Wind-Rotolo, M.; De Velasco, G.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis

Meeting Abstract

Voss, M. H.; Kuo, F.; Sanchez, A.; Ostrovnaya, I.; Cheng, Y.; Patel, P.; Marker, M.; Reising, A.; Chan, T. A. T.; Motzer, R. J.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)

Meeting Abstract

Vuky, J.; Balar, A. V.; Castellano, D. E.; O'Donnell, P. H.; Grivas, P.; Bellmunt, J.; Powles, T.; Bajorin, D. F.; Hahn, N. M.; De Wit, R.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel

Meeting Abstract

Tripathi, A.; Xie, W.; Sweeney, C.; Choudhury, A. D.; Pomerantz, M.; Wei, X. X.; Taplin, M. E.; Choueiri, T. K.; Lee, G. S. M.; Kantoff, P. W.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC)

Meeting Abstract

Tannir, N. M.; Naing, A.; Infante, J. R.; Papadopoulos, K. P.; Wong, D. J. L.; Korn, M.; Aljumaily, R.; Autio, K. A.; Pant, S.; Bauer, T. M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma

Meeting Abstract

Tannir, N. M.; Motzer, R. J.; Agarwal, N.; Liu, P. Y.; Whiting, S. H.; O'Keeffe, B.; Tran, X.; Fiji, G. P.; Escudier, B.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save